Survival analysis after liver resection for hepatocellular carcinoma: A consecutive cohort of 1002 patients

Lee, Eung Chang; Kim, Seong Hoon; Park, Hyeongmin; Lee, Seung Duk; Lee, Soon-Ae; Park, Sang-Jae

doi:10.1111/jgh.13632

Cited by 55 publications

(35 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Besides, with the prolongation of OS, the proportion of HCC samples in the high-risk group decreased gradually in relation to the total samples (Figure 2(c)). These 3 Journal of Immunology Research findings were consistent with the clinical findings that HCC patients did not relapse within 5 years after therapy, the OS was greatly improved and the recurrence rate gradually reduced [20]. Also, we analyzed the OS of HCC samples based on the nine-IRGP signature using the KM curve.…”

Section: Validation Of the Irgp Prognosticsupporting

confidence: 84%

Identification and Validation of Immune-Related Gene Prognostic Signature for Hepatocellular Carcinoma

Chen

Tang

et al. 2020

Journal of Immunology Research

View full text Add to dashboard Cite

Immune-related genes (IRGs) have been identified as critical drivers of the initiation and progression of hepatocellular carcinoma (HCC). This study is aimed at constructing an IRG signature for HCC and validating its prognostic value in clinical application. The prognostic signature was developed by integrating multiple IRG expression data sets from TCGA and GEO databases. The IRGs were then combined with clinical features to validate the robustness of the prognostic signature through bioinformatics tools. A total of 1039 IRGs were identified in the 657 HCC samples. Subsequently, the IRGs were subjected to univariate Cox regression and LASSO Cox regression analyses in the training set to construct an IRG signature comprising nine immune-related gene pairs (IRGPs). Functional analyses revealed that the nine IRGPs were associated with tumor immune mechanisms, including cell proliferation, cell-mediated immunity, and tumorigenesis signal pathway. Concerning the overall survival rate, the IRGPs distinctly grouped the HCC samples into the high- and low-risk groups. Also, we found that the risk score based on nine IRGPs was related to clinical and pathologic factors and remained a valid independent prognostic signature after adjusting for tumor TNM, grade, and grade in multivariate Cox regression analyses. The prognostic value of the nine IRGPs was further validated by forest and nomogram plots, which revealed that it was superior to the tumor TNM, grade, and stage. Our findings suggest that the nine-IRGP signature can be effective in determining the disease outcomes of HCC patients.

show abstract

Section: Validation Of the Irgp Prognosticsupporting

confidence: 84%

Identification and Validation of Immune-Related Gene Prognostic Signature for Hepatocellular Carcinoma

Chen

Tang

et al. 2020

Journal of Immunology Research

View full text Add to dashboard Cite

show abstract

“…Worldwide, the most common type of primary liver cancer is hepatocellular carcinoma (HCC)[ 1 ]. Hepatic resection is potentially curative for early-stage HCC if adequate reserve liver function is present[ 2 ]; however, the death rate from HCC remains high due to the high recurrence rate following hepatectomy[ 3 - 5 ]. Recently, a screening program for detecting early-stage disease in high-risk patients was found to improve surgical outcomes[ 6 ].…”

Section: Introductionmentioning

confidence: 99%

Prognostic role of alpha-fetoprotein response after hepatocellular carcinoma resection

Rungsakulkij¹,

Suragul²,

Mingphruedhi³

et al. 2018

WJCC

View full text Add to dashboard Cite

AIMTo investigate whether the change in pre-/post-operation serum alpha-fetoprotein (AFP) levels is a predictive factor for hepatocellular carcinoma (HCC) outcomes.METHODSWe retrospectively analyzed 334 HCC patients who underwent hepatic resection at our hospital between January 2006 and December 2016. The patients were classified into three groups according to their change in serum AFP levels: (1) the normal group, pre-AFP ≤ 20 ng/mL and post-AFP ≤ 20 ng/mL; (2) the response group, pre-AFP > 20 ng/mL and post-AFP decrease of ≥ 50% of pre-AFP; and (3) the non-response group, pre-AFP level > 20 ng/mL and post-AFP decrease of < 50% or higher than pre-AFP level, or any pre-AFP level < 20 ng/mL but post-AFP >20 ng/mLRESULTSUnivariate and multivariate analyses revealed that multiple tumors [hazard ratio (HR): 1.646, 95%CI: 1.15-2.35, P < 0.05], microvascular invasion (mVI) (HR: 1.573, 95%CI: 1.05-2.35, P < 0.05), and the non-response group (HR: 2.425, 95% CI: 1.42-4.13, P < 0.05) were significant independent risk factors for recurrence-free survival. Similarly, multiple tumors (HR: 1.99, 95%CI: 1.12-3.52, P < 0.05), mVI (HR: 3.24, 95%CI: 1.77-5.90, P < 0.05), and the non-response group (HR: 3.62, 95%CI: 1.59-8.21, P < 0.05) were also significant independent risk factors for overall survival. The non-response group had significantly lower overall survival rates and recurrence-free survival rates than both the normal group and the response group (P < 0.05). Thus, patients with no response regarding post-surgery AFP levels were associated with poor outcomes.CONCLUSIONSerum AFP responses are significant prognostic factors for the surgical outcomes of HCC patients, suggesting post-resection AFP levels can direct the management of HCC patients.

show abstract

“…Hepatocellular carcinoma (HCC), as the third leading cause of cancer-related mortality worldwide, is a common malignant tumor that seriously endangers human health [1][2][3]. HCC was diagnosed till advanced stages for lacking of effective therapies [4][5][6].…”

Section: Introductionmentioning

confidence: 99%

“…HCC was diagnosed till advanced stages for lacking of effective therapies [4][5][6]. At present, partial hepatectomy is a relative curative treatment preferentially for primary HCC patients, which can effectively treat tumor and improve the survival rate of patients [2,[7][8][9]. Regrettably, 70-80% of patients undergo tumor recurrence within 5 years after surgery, greatly reducing the survival rate after surgery [10].…”

Section: Introductionmentioning

confidence: 99%

Homotypic cell membrane-cloaked biomimetic nanocarrier for the accurate photothermal-chemotherapy treatment of recurrent hepatocellular carcinoma

et al. 2020

View full text Add to dashboard Cite

Background: Tumor recurrence in patients after surgery severely reduces the survival rate of surgical patients. Targeting and killing recurrent tumor cells and tissues is extremely important for the cancer treatment. Results: Herein, we designed a nano-biomimetic photothermal-controlled drug-loading platform HepM-TSL with good targeting ability and immunocompatibility for the treatment of recurrent hepatocellular carcinoma. HepM-TSL can accurately target the recurrent tumor area with the aid of the cloaked homotypic cell membrane and release the chemotherapy drugs in a controlled manner. In vivo results have confirmed that HepM-TSL loaded with drugs and photosensitizer achieves the synergistic treatment of recurrent hepatocellular carcinoma with good therapeutic effect and slight side effects. Conclusion: Accordingly, HepM-TSL provides a sound photothermal-chemotherapy synergistic strategy for the treatment of other recurrent cancers besides of recurrent hepatocellular carcinoma.

show abstract

Survival analysis after liver resection for hepatocellular carcinoma: A consecutive cohort of 1002 patients

Abstract: Survival of patients with HCC after resection should be stratified by various perioperative clinicopathological factors. Platelet count and intraoperative EBL could be considered as one of the powerful predictors of the prognosis and recurrence of HCC in such patients.

Cited by 55 publications

References 41 publications

Identification and Validation of Immune-Related Gene Prognostic Signature for Hepatocellular Carcinoma

Identification and Validation of Immune-Related Gene Prognostic Signature for Hepatocellular Carcinoma

Prognostic role of alpha-fetoprotein response after hepatocellular carcinoma resection

Homotypic cell membrane-cloaked biomimetic nanocarrier for the accurate photothermal-chemotherapy treatment of recurrent hepatocellular carcinoma

Contact Info

Product

Resources

About